Widely used:Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$260 Mln
P/E Ratio
--
P/B Ratio
4.6
Industry P/E
--
Debt to Equity
0.59
ROE
-0.38 %
ROCE
-17.58 %
Div. Yield
0 %
Book Value
0.3
EPS
-0.11
CFO
$-437.24 Mln
EBITDA
$-527.05 Mln
Net Profit
$-541.28 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Cerus (CERS)
| -12.34 | -13.46 | -31.47 | -18.67 | -32.60 | -24.92 | -11.90 |
|
BSE Sensex*
| 2.25 | 3.09 | 6.16 | 8.51 | 12.08 | 20.31 | 11.40 |
|
S&P Small-Cap 600#
| -5.82 | -5.34 | -13.73 | -6.30 | 5.30 | 2.98 | 5.53 |
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
|
|---|---|---|---|---|---|---|---|
|
Cerus (CERS)
| -28.51 | -40.82 | -46.40 | -1.59 | 63.98 | -16.77 | 49.67 |
|
S&P Small-Cap 600
| 7.01 | 13.89 | -17.42 | 25.27 | 9.57 | 20.86 | -9.70 |
|
BSE Sensex
| 8.10 | 18.74 | 4.44 | 21.99 | 15.75 | 14.38 | 5.87 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | P/E Ratio | ROE |
|---|---|---|---|---|
| 12.93 | 10,562.04 | 12.43 | 12.69 | |
| 72.80 | 10,050.19 | 97.07 | 2.52 | |
| 163.74 | 8,847.72 | -- | -25.23 | |
| 299.78 | 11,550.00 | 278.74 | 3.65 |
Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological... replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. The company offers INTERCEPT Blood Systems for platelets and plasma, which is designed to inactivate blood-borne pathogens in platelets and plasma donated for transfusion; INTERCEPT Blood System for red blood cells to inactivate blood-borne pathogens in red blood cells donated for transfusion; and INTERCEPT Blood System for Cryoprecipitation that uses its plasma system to produce pathogen reduced cryoprecipitated fibrinogen complex for the treatment and control of bleeding, including massive hemorrhage associated with fibrinogen deficiency, as well as pathogen reduced plasma and cryoprecipitate reduced. It sells platelet and plasma systems through its direct sales force and distributors in the United States, Europe, the Commonwealth of Independent States, the Middle East, Latin America, and internationally. The company was incorporated in 1991 and is headquartered in Concord, California. Read more
President, CEO & Director
Mr. William M. Greenman
President, CEO & Director
Mr. William M. Greenman
Headquarters
Concord, CA
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Cerus Corporation (CERS) stood at $ 201 Mln as on 31-Dec-24
The share price of Cerus Corporation (CERS) is $1.35 (NASDAQ) as of 25-Apr-2025 16:00 EDT. Cerus Corporation (CERS) has given a return of -32.6% in the last 3 years.
Cerus Corporation (CERS) has a market capitalisation of $ 260 Mln as on 25-Apr-2025. As per Value Research classification, it is a Small Cap company.
Since, TTM earnings of Cerus Corporation (CERS) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Cerus Corporation (CERS) and enter the required number of quantities and click on buy to purchase the shares of Cerus Corporation (CERS).
Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. The company offers INTERCEPT Blood Systems for platelets and plasma, which is designed to inactivate blood-borne pathogens in platelets and plasma donated for transfusion; INTERCEPT Blood System for red blood cells to inactivate blood-borne pathogens in red blood cells donated for transfusion; and INTERCEPT Blood System for Cryoprecipitation that uses its plasma system to produce pathogen reduced cryoprecipitated fibrinogen complex for the treatment and control of bleeding, including massive hemorrhage associated with fibrinogen deficiency, as well as pathogen reduced plasma and cryoprecipitate reduced. It sells platelet and plasma systems through its direct sales force and distributors in the United States, Europe, the Commonwealth of Independent States, the Middle East, Latin America, and internationally. The company was incorporated in 1991 and is headquartered in Concord, California.
The CEO & director of Mr. William M. Greenman. is Cerus Corporation (CERS), and CFO & Sr. VP is Mr. William M. Greenman.
There is no promoter pledging in Cerus Corporation (CERS).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
1,078
|
|
|
1,054
|
|
|
964
|
|
|
853
|
| Cerus Corporation (CERS) | Ratios |
|---|---|
|
Return on equity(%)
|
-38.45
|
|
Operating margin(%)
|
-6.59
|
|
Net Margin(%)
|
-11.6
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Cerus Corporation (CERS) was $0 Mln.
$-0.01
(
